Ligand Pharmaceuticals Incorporated (LGND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.04B
Last updated: Nov 17, 2026 at 4:20 PM ET
Ligand Pharmaceuticals Incorporated (LGND) Statistics
Ligand Pharmaceuticals (LGND) has a market cap of $6.04B and an enterprise value of $7.11B. Its trailing P/E of 64.7x is above its 10-year median of 23.8x.
Total Valuation
Enterprise value is 17.77% above the market cap, as debt exceeds cash.
| Market Cap | $6.04B |
|---|---|
| Enterprise Value | $7.11B |
| Latest price (Nov 17, 2026) | $293.81 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 23.1x and 6.1x. Its year-end P/E ranged from 11.7x to 42.3x from 2016 to 2025.
| P/E Ratio | 64.7x |
|---|---|
| Forward P/E | 30.3x |
| P/S Ratio | 23.1x |
| Forward P/S | 20.7x |
| P/B Ratio | 6.1x |
| P/TBV Ratio | 13.0x |
| P/FCF Ratio | 64.7x |
| P/OCF Ratio | 66.3x |
| PEG Ratio | 3.8 |
Enterprise Valuation
Counting debt and cash, the company is valued at 184.9x EBITDA and 76.5x free cash flow.
| EV / Earnings | 138.1x |
|---|---|
| EV / Sales | 28.0x |
| EV / EBITDA | 184.9x |
| EV / FCF | 76.5x |
Price Statistics
The stock is up 46.28% over 52 weeks and trades 2.75% below its 50-day average.
| Beta (1Y) | 0.94 |
|---|---|
| 52-Week Change | +46.28% |
| 1-Month Change | -1.17% |
| 3-Month Change | +1.07% |
| 6-Month Change | +41.40% |
| 5-Year Change | +121.15% |
| 10-Year Change | +237.15% |
| Total Return (1Y) | +46.28% |
| Total Return (3Y CAGR) | +71.90% |
| Total Return (5Y CAGR) | +12.83% |
| Return vs SPY (1Y) | +30.34% |
| Max Drawdown (1Y) | -14.70% |
| Max Drawdown (3Y) | -25.58% |
| Sharpe Ratio (1Y) | 0.96 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $302.13 |
| 200-Day Average | $259.40 |
| 52-Week Range | $175.89 to $326.63 |
| RSI (14 Days) | 41.4 |
| Average Volume (20 Days) | 224.25K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.22x current liabilities, and total debt is 1.17x shareholder equity.
| Current Ratio | 1.22x |
|---|---|
| Quick Ratio | 1.19x |
| Debt / Equity | 1.17x |
| Debt / EBITDA | 30.08x |
| Debt / FCF | 12.45x |
| Interest Coverage | 0.15x |
Returns and Efficiency
Return on invested capital is 0.06% over the last 12 months, against a 5-year average of 2.32%.
| Return on Equity (ROE) | 5.35% |
|---|---|
| Return on Assets (ROA) | 2.30% |
| Return on Invested Capital (ROIC) | 0.06% |
| ROE (5Y Average) | 4.11% |
| ROA (5Y Average) | 2.84% |
| ROIC (5Y Average) | 2.32% |
| Asset Turnover | 0.14x |
| Inventory Turnover | 0.98x |
| Receivables Turnover | 3.38x |
| Cash Conversion Cycle | 278 days |
Taxes
Income tax took 2.41% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.27M |
|---|---|
| Effective Tax Rate | 2.41% |
Scores
LGND has an Altman Z-Score of 3.28, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.28 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $253.83M over the last 12 months is up 1.03% from the 12 months before.
| Revenue | $253.83M |
|---|---|
| Revenue Growth (YoY) | +1.03% |
| Gross Profit | $241.70M |
| Operating Income | $24.04M |
| Pretax Income | $52.73M |
| Net Income | $51.46M |
| Reported EPS (TTM) | $4.54 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 42.94% of the $2.24B in total assets.
| Cash and Equivalents | $55.96M |
|---|---|
| Total Debt | $1.13B |
| Net Debt | $1.07B |
| Net Debt Per Share | $53.72 |
| Working Capital | $107.67M |
| Shareholder Equity | $961.76M |
| Book Value Per Share | $48.18 |
| Tangible Book Value | $451.86M |
| Tangible Book Per Share | $22.64 |
| Total Assets | $2.24B |
| Total Liabilities | $1.28B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $405.00K of capital spending, operating cash flow left $90.63M of free cash flow.
| Operating Cash Flow | $91.03M |
|---|---|
| Capital Expenditures | $405.00K |
| Free Cash Flow | $90.63M |
| FCF Per Share | $4.55 |
| Depreciation and Amortization | $38.69M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 9.47%, against a 5-year average of 11.08%.
| Gross Margin | 95.22% |
|---|---|
| Operating Margin | 9.47% |
| Pretax Margin | 20.77% |
| Net Margin | 20.27% |
| FCF Margin | 35.70% |
| Gross Margin (5Y Average) | 85.46% |
| Operating Margin (5Y Average) | 11.08% |
| Net Margin (5Y Average) | 18.08% |
Growth
Revenue grew 10.96% a year over 3 years, and EPS 14.98% a year.
| Revenue Growth (3Y CAGR) | +10.96% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.39% |
| EPS Growth (3Y CAGR) | +14.98% |
| EPS Growth (5Y CAGR) | +8.30% |
| FCF Growth (3Y CAGR) | -25.84% |
| FCF Growth (5Y CAGR) | -0.49% |
| Operating Income Growth (3Y CAGR) | +138.11% |
| Book Value Per Share Growth (2Y CAGR) | +10.16% |
| Tangible Book Per Share Growth (2Y CAGR) | +39.19% |
Dividends and Yields
LGND does not pay a dividend. Its free cash flow yield is 1.55%.
| Earnings Yield | 1.55% |
|---|---|
| FCF Yield | 1.55% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-6 reverse split on Nov 22, 2010.
| Last Split Date | Nov 22, 2010 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Peer Position
Against 3 similar companies, LGND has the 3rd highest P/E.
P/E RatioPeer median 87.1x
P/S RatioPeer median 8.6x
ROICPeer median -36.34%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.26%
| P/E Ratio | 64.7x vs 87.1x median |
|---|---|
| P/S Ratio | 23.1x vs 8.6x median |
| ROIC | 0.06% vs -36.34% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1.03% vs +14.26% median |
Analyst Forecast
Consensus estimates put revenue growth at 19.70% and EPS growth at 32.79% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +19.70% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +32.79% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LGND
What is LGND's market cap?
Ligand Pharmaceuticals has a market cap of $6.04B. Its enterprise value, which adds debt and subtracts cash, is $7.11B.
What is LGND's P/E ratio?
Ligand Pharmaceuticals has a trailing P/E ratio of 64.7x and a forward P/E of 30.3x.
How many shares of LGND are outstanding?
Ligand Pharmaceuticals has 19.96M shares outstanding. The count is up 1.96% from a year earlier.
Does LGND pay a dividend?
No. Ligand Pharmaceuticals does not pay a dividend.
How much debt does LGND have?
Ligand Pharmaceuticals has $1.13B of total debt and $55.96M of cash and equivalents, a net debt position of $1.07B.
LGND pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors